First-pass extracted concept

combinational RNAi-based therapy

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

combinational RNAi-based therapies, combinational RNAi therapy, multigene RNAi technology

Extracted Explainers

What the tool is doing

This concept refers to using combinations of RNAi agents to silence multiple cancer-relevant genes at the same time. The abstract frames it as a strategy to address multifaceted signaling and effector pathways in cancer.

Source 1DOI PubMed

What problem it solves

It is presented as a way to overcome the limitations of single-target RNAi and resistance mechanisms in evolving cancer cells.

Source 1DOI PubMed

What it does not solve

The abstract notes that formulation challenges remain, so it does not by itself resolve delivery and formulation barriers.

Source 1DOI PubMed

Alternatives

The abstract contrasts combinational RNAi therapy with single RNAi therapies and with traditional anticancer treatment regimes.

Source 1DOI PubMed

Evidence Snippets

the advancement of combinational RNAi-based therapies

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1comparative performancesupports2025Source 1DOI PubMed

The review's systematic analysis of preclinical tumor inhibition studies found that combinational RNAi therapy outperformed single RNAi therapies in average tumor volume reduction.

Claim 2limitationsupports2025Source 1DOI PubMed

Formulation of combinational RNAi-based therapies has important challenges and future development needs.

Claim 3rationalesupports2025Source 1DOI PubMed

Combinational RNAi-based therapies are being advanced because multifaceted cancer signaling networks can adapt to evade single-target RNAi interventions.